IBA - Regulated Information

    IBA - Regulated Information

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, August 1st, 2024 06:00

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on July 30, 2024.

In its notification, FMR LLC indicated that following an acquisition or disposal of securities or voting rights. Its total participation in IBA SA decreased and its participation in IBA shares with voting rights crossed the threshold of 1% on 25/07/2024.

Content of the notification

• Reason for the notification: Acquisition or disposal of securities or voting rights
• Notification by: A parent company or controlling person
• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 25/07/2024
• Threshold crossed (in %) : 1%
• Denominator : 40.595.290
• Notified details: (extract of the received notification form)

• Full chain of controlled undertakings through which the holding is effectively held

FIAM LLC is controlled by FIAM Holdings LLC.FIAM Holdings LLC, Fidelity Management & Research Company LLC are controlled by FMR LLC.FMR LLC is not a controlled undertaking

• Additional information

The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC and Fidelity Management & Research Company LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

• About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2.000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com

For further information, please contact:

Valérie Van Impe
Paralegal
[phone]
[e-mail]

 

Attachment

• 20240801-IBA-FMR LLC_transparency EN